<DOC>
	<DOC>NCT02492321</DOC>
	<brief_summary>This is a Phase III multi-center, double-masked, vehicle-controlled, randomized, parallel group study evaluating the efficacy, safety and tolerability of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe allergic conjunctivitis (AC) three times daily for 4 weeks. Approximately 250 subjects at approximately 8 centers in the US will be screened and enrolled into the study.</brief_summary>
	<brief_title>A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>Give written informed consent and any authorization required by local law (e.g., Protected Health Information waiver) prior to performing any study procedures; Are â‰¥18 years of age; Have a positive history of ocular allergies during ragweed pollen season; Have signs and symptoms of allergic conjunctivitis in both eyes; If female and of childbearing potential, she must not be pregnant or lactating Have signs of ocular infection; Have a known history of alcohol or drug abuse; Have been exposed to an investigational drug or device within 30 days of the study; Have planned surgery (ocular or systemic) during the trial period or within 30 days after</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>